Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas
This study investigated potential markers for predicting nonfunctioning pituitary adenoma (NFPA) invasion and recurrence by high-throughput tissue microarray analyses. We retrospectively studied two groups of patients: 60 nonrecurrent NFPA cases that included noninvasion and invasion subtypes and 43...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2019/5731639 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524478921670656 |
|---|---|
| author | Xiaohui Yao Yazhuo Zhang Lijuan Wu Rui Cheng Chuzhong Li Chongxiao Qu Hongming Ji |
| author_facet | Xiaohui Yao Yazhuo Zhang Lijuan Wu Rui Cheng Chuzhong Li Chongxiao Qu Hongming Ji |
| author_sort | Xiaohui Yao |
| collection | DOAJ |
| description | This study investigated potential markers for predicting nonfunctioning pituitary adenoma (NFPA) invasion and recurrence by high-throughput tissue microarray analyses. We retrospectively studied two groups of patients: 60 nonrecurrent NFPA cases that included noninvasion and invasion subtypes and 43 recurrent cases that included primary NFPA. A total of 31 paired patient samples were evaluated (12 patients with one surgery and 31 who had undergone two operations, with both tumors analyzed). Expressions of nuclear receptor subfamily 2 group C member 2 (NR2C2), B cell translocation gene 2, T-box-19 (TBX19), and cyclin-dependent kinase 2 (CDK2) in surgically resected specimens were assessed by immunohistochemistry. The relationships between marker expression and clinical characteristics including age, sex, tumor volume, and follow-up time were analyzed. Tumor volume and invasion as well as follow-up time were significantly associated with invasion and recurrence (P < 0.01). Of the 60 nonrecurrent samples, 15/41 and 13/19 showed high NR2C2 expression in the noninvasion and invasion groups, respectively (χ2 =5.287, P = 0.021). NR2C2 was also overexpressed in 43 primary recurrent cases (χ2 =5.433, P = 0.02), whereas CDK2 (χ2 = 11.242, P = 0.001) and TBX19 (χ2 = 4.875, P = 0.027) were downregulated. In the 31 paired samples, NR2C2 was more highly expressed in the recurrent as compared to the primary tumor. High NR2C2 expression was associated with NFPA invasion, recurrence, and progression, while TBX19 and CDK2 were associated with NFPA recurrence. |
| format | Article |
| id | doaj-art-a74650f160f14fbe9f6166f7a2b4bf97 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-a74650f160f14fbe9f6166f7a2b4bf972025-02-03T05:53:05ZengWileyInternational Journal of Endocrinology1687-83371687-83452019-01-01201910.1155/2019/57316395731639Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary AdenomasXiaohui Yao0Yazhuo Zhang1Lijuan Wu2Rui Cheng3Chuzhong Li4Chongxiao Qu5Hongming Ji6Shanxi Provincial People’s Hospital, Taiyuan, Shanxi Province, ChinaKey Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaShanxi Provincial People’s Hospital, Taiyuan, Shanxi Province, ChinaShanxi Provincial People’s Hospital, Taiyuan, Shanxi Province, ChinaKey Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaShanxi Provincial People’s Hospital, Taiyuan, Shanxi Province, ChinaShanxi Provincial People’s Hospital, Taiyuan, Shanxi Province, ChinaThis study investigated potential markers for predicting nonfunctioning pituitary adenoma (NFPA) invasion and recurrence by high-throughput tissue microarray analyses. We retrospectively studied two groups of patients: 60 nonrecurrent NFPA cases that included noninvasion and invasion subtypes and 43 recurrent cases that included primary NFPA. A total of 31 paired patient samples were evaluated (12 patients with one surgery and 31 who had undergone two operations, with both tumors analyzed). Expressions of nuclear receptor subfamily 2 group C member 2 (NR2C2), B cell translocation gene 2, T-box-19 (TBX19), and cyclin-dependent kinase 2 (CDK2) in surgically resected specimens were assessed by immunohistochemistry. The relationships between marker expression and clinical characteristics including age, sex, tumor volume, and follow-up time were analyzed. Tumor volume and invasion as well as follow-up time were significantly associated with invasion and recurrence (P < 0.01). Of the 60 nonrecurrent samples, 15/41 and 13/19 showed high NR2C2 expression in the noninvasion and invasion groups, respectively (χ2 =5.287, P = 0.021). NR2C2 was also overexpressed in 43 primary recurrent cases (χ2 =5.433, P = 0.02), whereas CDK2 (χ2 = 11.242, P = 0.001) and TBX19 (χ2 = 4.875, P = 0.027) were downregulated. In the 31 paired samples, NR2C2 was more highly expressed in the recurrent as compared to the primary tumor. High NR2C2 expression was associated with NFPA invasion, recurrence, and progression, while TBX19 and CDK2 were associated with NFPA recurrence.http://dx.doi.org/10.1155/2019/5731639 |
| spellingShingle | Xiaohui Yao Yazhuo Zhang Lijuan Wu Rui Cheng Chuzhong Li Chongxiao Qu Hongming Ji Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas International Journal of Endocrinology |
| title | Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas |
| title_full | Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas |
| title_fullStr | Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas |
| title_full_unstemmed | Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas |
| title_short | Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas |
| title_sort | immunohistochemical study of nr2c2 btg2 tbx19 and cdk2 expression in 31 paired primary recurrent nonfunctioning pituitary adenomas |
| url | http://dx.doi.org/10.1155/2019/5731639 |
| work_keys_str_mv | AT xiaohuiyao immunohistochemicalstudyofnr2c2btg2tbx19andcdk2expressionin31pairedprimaryrecurrentnonfunctioningpituitaryadenomas AT yazhuozhang immunohistochemicalstudyofnr2c2btg2tbx19andcdk2expressionin31pairedprimaryrecurrentnonfunctioningpituitaryadenomas AT lijuanwu immunohistochemicalstudyofnr2c2btg2tbx19andcdk2expressionin31pairedprimaryrecurrentnonfunctioningpituitaryadenomas AT ruicheng immunohistochemicalstudyofnr2c2btg2tbx19andcdk2expressionin31pairedprimaryrecurrentnonfunctioningpituitaryadenomas AT chuzhongli immunohistochemicalstudyofnr2c2btg2tbx19andcdk2expressionin31pairedprimaryrecurrentnonfunctioningpituitaryadenomas AT chongxiaoqu immunohistochemicalstudyofnr2c2btg2tbx19andcdk2expressionin31pairedprimaryrecurrentnonfunctioningpituitaryadenomas AT hongmingji immunohistochemicalstudyofnr2c2btg2tbx19andcdk2expressionin31pairedprimaryrecurrentnonfunctioningpituitaryadenomas |